Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Christopher Ryan, MD, Oregon Health & Science University, Knight Cancer Institute
Videos
Post-Nephrectomy Everolimus for Patients With Renal Cell Carcinoma: Findings From the EVEREST Trial
08/19/2022
Christopher Ryan, MD, discusses findings from the phase 3 EVEREST trial, which investigated the effect of adjuvant treatment, everolimus, an mTOR inhibitor, on recurrence-free survival in patients receiving nephrectomy for renal cell...
Christopher Ryan, MD, discusses findings from the phase 3 EVEREST trial, which investigated the effect of adjuvant treatment, everolimus, an mTOR inhibitor, on recurrence-free survival in patients receiving nephrectomy for renal cell...
Christopher Ryan, MD, discusses...
08/19/2022
Oncology

Advertisement

Prof Vijay Maruti Patil, MBBS, MD, DM, Tata Memorial Centre, Mumbai, India
Videos
Docetaxel Added to Radiation Improves Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma
08/11/2022
Prof Vijay Maruti Patil, MBBS, MD, DM, discusses findings from a phase 3 trial that explored the use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.
Prof Vijay Maruti Patil, MBBS, MD, DM, discusses findings from a phase 3 trial that explored the use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.
Prof Vijay Maruti Patil, MBBS,...
08/11/2022
Oncology

Advertisement

Yi-Bin Chen, MD, Massachusetts General Hospital
Videos
Itacitinib vs Placebo Combined With Corticosteroids for GVHD: Findings From the GRAVITAS-301 Trial
07/25/2022
Yi-Bin Chen, MD, discusses results from the phase 3 GRAVITAS-301 trial, which evaluated itacitinib vs placebo, both in combination with corticosteroids, for the initial treatment of patients with acute GVHD.
Yi-Bin Chen, MD, discusses results from the phase 3 GRAVITAS-301 trial, which evaluated itacitinib vs placebo, both in combination with corticosteroids, for the initial treatment of patients with acute GVHD.
Yi-Bin Chen, MD, discusses...
07/25/2022
Oncology
Ian Davis, MBBS, Monash University
Videos
Enzalutamide Added to Testosterone Suppression Improves OS in Metastatic Hormone-Sensitive Prostate Cancer
07/21/2022
Ian Davis, MBBS, PhD, FRACP, FAChPM, discusses updated OS outcomes from the ENZAMET trial, exploring testosterone suppression plus either enzalutamide or a conventional non-steroidal anti-androgen in metastatic hormone-sensitive prostate...
Ian Davis, MBBS, PhD, FRACP, FAChPM, discusses updated OS outcomes from the ENZAMET trial, exploring testosterone suppression plus either enzalutamide or a conventional non-steroidal anti-androgen in metastatic hormone-sensitive prostate...
Ian Davis, MBBS, PhD, FRACP,...
07/21/2022
Oncology
Videos
Treating Locally Advanced Basal Cell Carcinoma
07/14/2022
Evan Lipson, MD, and Megan Schollenberger, CRNP, discuss a patient case of recurrent, locally advanced basal cell carcinoma of the left nasal ala and medial canthus, following the patient through multiple lines of therapy.
Evan Lipson, MD, and Megan Schollenberger, CRNP, discuss a patient case of recurrent, locally advanced basal cell carcinoma of the left nasal ala and medial canthus, following the patient through multiple lines of therapy.
Evan Lipson, MD, and Megan...
07/14/2022
Oncology

Advertisement

Erika Martinelli, MD, PhD, University of Campania “Luigi Vanvitelli”
Videos
Third-Line Cetuximab Rechallenge Demonstrates Therapeutic Effectiveness in Metastatic Colorectal Cancer
07/03/2022
Erika Martinelli, MD, PhD, discusses findings from a follow-up analysis of the CRICKET and CAVE trials evaluating third-line cetuximab rechallenge combined with irinotecan or avelumab for patients with RAS wild-type metastatic colorectal...
Erika Martinelli, MD, PhD, discusses findings from a follow-up analysis of the CRICKET and CAVE trials evaluating third-line cetuximab rechallenge combined with irinotecan or avelumab for patients with RAS wild-type metastatic colorectal...
Erika Martinelli, MD, PhD,...
07/03/2022
Oncology
Ignacio Garrido-Laguna, MD, Huntsman Cancer Institute
Videos
Entrectinib Yields Durable Responses, Manageable Safety in NTRK Fusion-Positive Gastrointestinal Cancers
07/03/2022
Ignacio Garrido-Laguna, MD, discusses findings from an updated integrated analysis exploring entrectinib in patients with NTRK fusion-positive gastrointestinal cancer.
Ignacio Garrido-Laguna, MD, discusses findings from an updated integrated analysis exploring entrectinib in patients with NTRK fusion-positive gastrointestinal cancer.
Ignacio Garrido-Laguna, MD,...
07/03/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use